Abivax Sets September 21 for Q2 2026 Earnings Release
The Paris-based biotech firm prepares to disclose its second-quarter financials, with analysts projecting a net loss of $0.9170 per share against expected revenue of $0.7990 million.
Abivax is scheduled to report its second-quarter financial results for fiscal year 2026 after the market close on Monday, September 21. The company, listed on the NASDAQ under the ticker ABVX, will provide an earnings call at 11:40 AM ET on the same day. According to data compiled by GN markets/earnings (en-US), market consensus projects a net loss of $0.9170 per share for the period. This figure reflects the ongoing costs associated with the firm's clinical-stage pipeline, specifically the development of obefazimod, an oral therapy targeting chronic inflammatory diseases.
Revenue expectations for the quarter stand at $0.7990 million, a figure consistent with the company’s pre-commercialization status. Abivax operates as a clinical-stage biotechnology enterprise headquartered in Paris, focusing on oral small-molecule therapies for immune-mediated conditions. The primary candidate, obefazimod, is designed to enhance the production of microRNA-124, a key regulator of inflammatory pathways. The drug is currently in development for ulcerative colitis and has also undergone evaluation for Crohn’s disease, representing the core value proposition for the firm's investors.
Current Valuation Metrics and Stock Performance
Abivax shares opened at $118.64 on Monday, trading within a one-year range that spans a low of $69.81 and a high of $148.83. The company’s market capitalization is currently valued at $10.35 billion. Technical indicators show a 50-day simple moving average of $124.83 and a 200-day simple moving average of $118.22. The firm carries a beta of 0.96, suggesting volatility roughly in line with the broader market, and a negative P/E ratio of -22.77, which is standard for a pre-revenue biotech entity focused on R&D rather than immediate profitability.
Analyst Ratings and Institutional Positioning
Wall Street sentiment remains mixed but leans positive, with a consensus rating of Moderate Buy and an average target price of $156.38. Recent actions include Truist Financial raising its price objective to $155.00 and Citizens JMP reaffirming a market outperform rating with a $187.00 target. Conversely, Weiss Ratings issued a sell rating in July. The broader analyst community includes one Strong Buy, thirteen Buys, one Hold, and one Sell rating, indicating a strong majority of bullish conviction despite the current net losses.
Institutional interest has increased recently, with several major asset managers adding to their positions. Caitong International Asset Management increased its holdings by 661.5% in the fourth quarter, while T. Rowe Price, &PARTNERS, SmartHarvest Portfolios, and Fox Run Management all initiated new stakes in the company. Institutional investors currently hold 47.91% of the outstanding shares, providing a significant base of long-term capital behind the firm’s clinical trials for ulcerative colitis and related inflammatory conditions.
